Tumors and the immune response interact in various ways. Tumors try to suppress the immune response in an effort to promote their growth and survival. The anti-tumor immune response, on the other hand, identifies tumor cells and kills them. Both tumors and the immune response elicit various mechanisms to combat the actions of the other.
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
Date: November 18, 2021 Time: 8:00am (PDT), 11:00am (EDT) Keep ahead in CAR T and CAR NK cell research. We introduce advanced techniques for generating and characterizing engineered immune c...
Date: November 16, 2021 Time: 8:00am (PDT), 11:00am (EDT) The unique suppressive function of regulatory T cells (Treg cells) makes them an interesting target cell population to study. In rec...
Date: November 4, 2021 Time: 8:00am (PDT), 11:00am (EDT) The promise of tissue clearing techniques in combination with 3D-immunofluorescence (IF) microscopy is revolutionary. Complex biologi...
Date: November 3, 2021 Time: 7:00am (PDT), 10:00am (EDT) The reconstitution of a fully functional human immune system in mouse after engraftment of purified hCD34+ hematopoietic cells provid...
Date: September 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) High-dimensional flow cytometry generates a wealth of data. Computational approaches can help to simplify the complexity of large d...
Date: October 26, 2021 Time: 8:00am (PDT), 11:00am (EDT) A complex interaction among heterogenous immune and tumor cells within the tumorous tissue not only influences tumor progression, but...
Date: October 14, 2021 Time: 8:00am (PDT), 11:00am (EDT) The primary role of B cells is to secrete antibodies, boosting our adaptive immune responses, making them an essential part of our im...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
Advances in cancer research have improved our understanding of the complex interactions between tumors, their microenvironment and the host immune response. The evolving research field of im...
Background: Localized prostate cancer is notable for tumor heterogeneity, and immune heterogeneity within tumor versus benign areas. B7-H3, a member of the B7 superfamily, is highly expresse...
T cells exquisitely discriminate between antigenic and self-peptide ligands presented on major histocompatibility complexes (pMHCs) despite subtle differences in affinities. This aspect of a...
While providing indispensable insight into immune processes, the live cell imaging of immune cells poses unique challenges due to their non-adherent nature. Suspension cells such as immune c...
Date: September 8, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Implanted biomedical devices comprise a major component of modern medicine and are essential for many clinical applications ranging...
Date: August 26, 2021 Time: 7:00am (PDT), 10:00am (EDT) Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with rising incidence and a remarkable resistance to current therapies. In t...
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral...
DATE: June 17, 2021 TIME: 07:00am PDT Colorectal cancer is a particularly challenging disease for immunotherapy given tumor heterogeneity. Multiplexed whole slide imaging allows deep context...
PD-L1 is a key inhibitor of T cell activation that is often over-expressed in cancer to escape immune surveillance and promote tumor progression. Blocking antibodies against PD-L1 or its rec...
Hypoxia is pervasive across human cancer and its association with poor outcomes and aggressive malignant phenotypes has been increasingly appreciated. Previously, we and others described how...
Learning Objectives: 1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity 2. Explain how PD-1 blockade leads...
Learning Objectives: 1. Learn about why Luminex’s xMAP bead-based technology is the gold-standard in multiplexing, including how xMAP emerged as the leading multiplexing platform for l...
This webinar will highlight the research solutions that Miltenyi Biotec has to offer for those investigating the roles of Tregs, NK cells, and Macrophages in the context of the tumor microen...
Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
Date: November 18, 2021 Time: 8:00am (PDT), 11:00am (EDT) Keep ahead in CAR T and CAR NK cell research. We introduce advanced techniques for generating and characterizing engineered immune c...
Date: November 16, 2021 Time: 8:00am (PDT), 11:00am (EDT) The unique suppressive function of regulatory T cells (Treg cells) makes them an interesting target cell population to study. In rec...
Date: November 4, 2021 Time: 8:00am (PDT), 11:00am (EDT) The promise of tissue clearing techniques in combination with 3D-immunofluorescence (IF) microscopy is revolutionary. Complex biologi...
Date: November 3, 2021 Time: 7:00am (PDT), 10:00am (EDT) The reconstitution of a fully functional human immune system in mouse after engraftment of purified hCD34+ hematopoietic cells provid...
Date: September 16, 2021 Time: 7:00am (PDT), 10:00am (EDT) High-dimensional flow cytometry generates a wealth of data. Computational approaches can help to simplify the complexity of large d...
Date: October 26, 2021 Time: 8:00am (PDT), 11:00am (EDT) A complex interaction among heterogenous immune and tumor cells within the tumorous tissue not only influences tumor progression, but...
Date: October 14, 2021 Time: 8:00am (PDT), 11:00am (EDT) The primary role of B cells is to secrete antibodies, boosting our adaptive immune responses, making them an essential part of our im...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
Advances in cancer research have improved our understanding of the complex interactions between tumors, their microenvironment and the host immune response. The evolving research field of im...
Background: Localized prostate cancer is notable for tumor heterogeneity, and immune heterogeneity within tumor versus benign areas. B7-H3, a member of the B7 superfamily, is highly expresse...
T cells exquisitely discriminate between antigenic and self-peptide ligands presented on major histocompatibility complexes (pMHCs) despite subtle differences in affinities. This aspect of a...
While providing indispensable insight into immune processes, the live cell imaging of immune cells poses unique challenges due to their non-adherent nature. Suspension cells such as immune c...
Date: September 8, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Implanted biomedical devices comprise a major component of modern medicine and are essential for many clinical applications ranging...
Date: August 26, 2021 Time: 7:00am (PDT), 10:00am (EDT) Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with rising incidence and a remarkable resistance to current therapies. In t...
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral...
DATE: June 17, 2021 TIME: 07:00am PDT Colorectal cancer is a particularly challenging disease for immunotherapy given tumor heterogeneity. Multiplexed whole slide imaging allows deep context...
PD-L1 is a key inhibitor of T cell activation that is often over-expressed in cancer to escape immune surveillance and promote tumor progression. Blocking antibodies against PD-L1 or its rec...
Hypoxia is pervasive across human cancer and its association with poor outcomes and aggressive malignant phenotypes has been increasingly appreciated. Previously, we and others described how...
Learning Objectives: 1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity 2. Explain how PD-1 blockade leads...
Learning Objectives: 1. Learn about why Luminex’s xMAP bead-based technology is the gold-standard in multiplexing, including how xMAP emerged as the leading multiplexing platform for l...
This webinar will highlight the research solutions that Miltenyi Biotec has to offer for those investigating the roles of Tregs, NK cells, and Macrophages in the context of the tumor microen...
Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
